Wegovy, an alternative anti-obesity drug to Ozempic needed for diabetics, arrives in pharmacies
Since it was discovered that Ozempic, a drug indicated for patients with diabetes. also served lose weight, The demand for this drug has increased sharply, and this has caused lack of goods in pharmacies at times causing problems for diabetics who required medications to control the disease. Now, however, enters the Spanish market, Vegovi, a drug with the same components, but which can only be prescribed to combat obesity and excess weight. The availability of this new drug starting this Wednesday, May 1, will allow the market to relax from the high demand for Ozempic, which is needed to combat type 2 diabetes and is also useful for people suffering from insulin intolerance. The Spanish state is the seventh in Europe and eleventh in the world to use the new therapy after it was approved by regulators including the European Medicines Agency.
By doctor’s prescription
How is he veg How Ozempic These are drugs that They can only be obtained by prescription, although the Spanish Agency for Medicines and Health Products (AEMPS) has detected the sale of Ozempic drugs in some pharmacies without a doctor’s prescription. The agency’s monitoring is being updated due to supply issues with GLP-1 analogues, which are approved to improve glycemic control in the treatment of adults with type 2 diabetes mellitus (T2DM) that is not well controlled by diet and exercise. L’AMPS warned that these medicines should under no circumstances be dispensed without a prescription.
However, the difference between Wegovy and Ozempic is that This second is financed by social insurance for diabetics.and those who take the drug to combat obesity or excess weight will have to opt for Wegovy, which Price 128 euros per month., the same as Ozempic unless it is subsidized by Social Security. Despite the high cost of this drug on the Spanish market, it is significantly cheaper than its price in the United States, where the monthly cost of Wegovy is about $1,500 and Ozempic is about a thousand dollars. Ozempic’s boom has been impressive in all markets where it is sold. In Catalonia, for example, the number of prescriptions for diabetes drugs from the Ozempic family has increased by 70% in two years.
Novo Nordisk – the goose that lays the golden eggs
Both Wegovy and Ozempic are produced. the same pharmaceutical company, the Danish Novo Nordisk, which thanks to these drugs has become the most valuable pharmaceutical company in Europe and is among the 20 largest companies in the world. Novo Nordisk, a century-old company, achieved sales of 23.72 billion euros in 2022. Novo Nordisk’s market value exceeds Denmark’s gross domestic product, a prestigious magazine recently explained. The science, who considered them to be the scientific advance of 2023 because of the benefits they bring. The Danish company spent 5.631 million euros to increase productionn, expanding its Danish plant in Kalundborg to meet strong demand for Wegovy and Ozempic.
In the early 1980s, researchersdiscovered GLP-1 while researching diabetes and blood sugar regulation.. Two years ago, the Danish pharmaceutical company Novo Nordisk received the green light in the United States to sell Ozempic for diabetes and Vegovi for obesity. The special effect of this drug, which contains the active ingredient semaglutide, is that it lowers blood sugar levels and regulates insulin. The drug targets a key hormone that helps reduce hunger and feel full after eating. Both drugs are administered in the same way: through pens, doses are administered intramuscularly once a week.
Obesity, a silent pandemic
Obesity is one of the most common chronic diseases. More It affects 650 million adults worldwide. In fact, obesity is considered a silent pandemic, and according to the latest World Obesity Atlas report from the World Obesity Federation (WFO), 51% of the world’s population will be overweight or obese from 2035 if the problem is not addressed. . reverse current trends.